FDA Approves Oral SERD Combo for ESR1+ Breast Cancer

Imlunestrant + abemaciclibWhat to know

30-second read

For Oncology

Who

ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that progressed on at least one prior endocrine therapy line.

What’s new

Full approval of imlunestrant (oral SERD) plus abemaciclib, alongside an expanded Guardant360 CDx liquid-biopsy clearance to identify eligible patients.

Evidence

EMBER-3's ESR1-mutated subgroup: median PFS 11.1 vs. 5.5 months for imlunestrant alone (95% CI 7.4–13.7 vs. 3.8–7.2).

Big advantage

Fully oral, and it keeps abemaciclib in play with a new endocrine partner rather than forcing a switch straight to chemotherapy.

Key consideration

The label requires confirming ESR1 by an FDA-authorized liquid biopsy — retest at progression, since the mutation typically emerges over time, not at diagnosis.

Availability

Approved 18 September 2026. Imlunestrant alone lists near $22,500 per 28-day supply; the doublet's combined price and payer coverage are not yet public.

Practice impactConsider for selected patients

A reasonable next step for a patient who tolerated abemaciclib and whose tumor carries an ESR1 mutation on repeat testing. It doesn't replace the testing decision; elacestrant or fulvestrant remain reasonable alternatives absent a documented mutation.

Read the full physician analysis

Full analysis · 8 min readFDA approval notice, 18 September 2026 · EMBER-3 (published subgroup data) · ASCO ctDNA/ESR1 testing guideline update

FDA gave full approval on 18 September 2026 to imlunestrant (Inluriyo), Eli Lilly's oral selective estrogen receptor degrader, in combination with abemaciclib (Verzenio), the company's CDK4/6 inhibitor, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed on endocrine therapy. FDA paired the drug approval with an expanded companion-diagnostic clearance for Guardant360 CDx, the blood-based liquid biopsy that identifies which patients carry the mutation. For a busy oncology practice, the regulatory event and the practice event are not quite the same thing: the drug approval is what made news, but the decision this approval actually hands physicians is a testing decision — when to draw the blood, and how to read what comes back.

A Second Partner for the Same CDK4/6 Inhibitor

Abemaciclib rechallenge — continuing a CDK4/6 inhibitor past progression by switching only its endocrine partner — already has trial support independent of this approval: the phase 3 postMONARCH trial showed that continuing abemaciclib with a new endocrine partner (fulvestrant) after progression on a prior CDK4/6 inhibitor improved progression-free survival over switching endocrine therapy alone. This approval gives that same strategy a second endocrine partner to use instead of fulvestrant: an oral SERD studied specifically alongside abemaciclib in the ESR1-mutated population, rather than fulvestrant's injectable, twice-monthly administration. It does not establish that imlunestrant is better than fulvestrant as abemaciclib's partner in a head-to-head sense — no such trial has been run — only that this particular pairing has its own approval and its own dedicated efficacy data.

That efficacy data is specific to a subgroup, and the subgroup is the whole point of the label. EMBER-3 was a three-arm phase 3 trial — imlunestrant alone, investigator's-choice endocrine therapy, and imlunestrant plus abemaciclib — enrolling ER-positive, HER2-negative advanced breast cancer previously treated with an aromatase inhibitor, with or without a CDK4/6 inhibitor. This approval rests on the ESR1-mutated subgroup, where the combination roughly doubled median progression-free survival over imlunestrant alone: 11.1 months versus 5.5 months. That is a different number from the trial's broader intent-to-treat result, and the label is written to the subgroup, not the full trial population — which is exactly why a patient's ESR1 status, not just her prior treatment history, is the gate this approval opens.

When to Order the Liquid Biopsy, and How Often

ASCO's guideline update on biomarker testing in ER-positive, HER2-negative metastatic breast cancer recommends blood-based ctDNA testing for ESR1 mutations at metastatic recurrence or at progression on endocrine therapy — not as a routine baseline test at initial diagnosis. The mutation is typically acquired: ESR1 mutations arise as a tumor develops resistance to aromatase-inhibitor therapy, so a test drawn before that resistance has had time to develop is more likely to come back negative than a test drawn at the moment of progression. ASCO's guidance also supports repeat testing over time rather than treating a single negative result as final, because a mutation that was not detectable at first progression can emerge later under continued treatment pressure. A blood draw has a practical advantage over a repeat tumor biopsy here: metastatic re-biopsy is invasive, not always feasible depending on the site of disease, and inconvenient to repeat serially in a way a blood draw is not.

Where It Sits Beside Elacestrant and Fulvestrant

Imlunestrant is not the only oral SERD approved for this population. Elacestrant (Orserdu) has been FDA-approved as monotherapy for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer since 2023, and a third oral SERD, vepdegestrant, has separately been paired with an expanded Guardant360 CDx clearance of its own — oncologists are moving toward a field with more than one biomarker-matched oral option, not a single default. The clearest practical difference between imlunestrant and elacestrant is monitoring, not efficacy: elacestrant's label requires a baseline lipid panel and periodic monitoring for hypercholesterolemia and hypertriglyceridemia, a requirement imlunestrant's label does not carry. Choosing among them in practice already depends on more than ESR1 status alone — co-mutations such as PIK3CA, AKT1 or PTEN, prior CDK4/6 inhibitor duration and tolerance, disease burden, and comorbidities all factor into oncologists' current decision-making at this treatment line, and this approval adds a combination option to that same decision rather than replacing it.

Two oral options for the same ESR1-mutated patient

	Imlunestrant + abemaciclib	Elacestrant (monotherapy)
Regulatory basis	Full approval, 18 Sept 2026 (combination)	Full approval, 2023 (monotherapy)
Administered with a CDK4/6 inhibitor	Yes — studied and labeled with abemaciclib	No — monotherapy only
Drug-specific monitoring	Abemaciclib's existing class warnings (blood counts, ILD/pneumonitis, hepatotoxicity, VTE)	Baseline and periodic lipid panel (hypercholesterolemia, hypertriglyceridemia)
Companion diagnostic	Guardant360 CDx (expanded clearance)	Guardant360 CDx (separately cleared)

Neither drug has been compared with the other in a head-to-head trial; the choice between them in practice turns on prior CDK4/6i tolerance, co-mutations and comorbidities, not on this table alone.

What Isn’t Settled Yet

Imlunestrant is more brain-penetrant than some prior endocrine agents, and a post-hoc analysis of EMBER-3 has been read as a signal of benefit in patients with central nervous system metastases — a population that is often underrepresented in registrational trials and undertreated by drugs that don't cross the blood-brain barrier well. Whether that signal holds specifically for the combination, rather than for imlunestrant alone, has not been established; it is a genuinely open question rather than a settled advantage of this approval. Reimbursement is the other open question. Guardant360 CDx already carries broad payer coverage, including a Medicare local coverage determination for advanced solid tumors, because it was cleared as a companion diagnostic for imlunestrant monotherapy in 2025 — that coverage predates this approval and should not need to be re-established. What has not yet been separately confirmed is a combined list price for the doublet or payer prior-authorization terms specific to prescribing both drugs together under the new indication; both drugs already carry their own individual specialty-pharmacy and prior-authorization pathways as previously marketed oncolytics, and nothing in the public record yet says the combination changes that pattern one way or the other.

• Retest for ESR1 at progression, by blood draw, rather than assuming a prior negative result still holds — the mutation is typically acquired under treatment pressure.
• Weigh CDK4/6i rechallenge with imlunestrant as a new endocrine partner for a patient who tolerated abemaciclib well, alongside fulvestrant-based rechallenge and elacestrant monotherapy as reasonable alternatives.
• Monitor per abemaciclib's existing label (blood counts, pulmonary symptoms, liver enzymes, VTE signs) — the combination has not introduced a new safety signal beyond abemaciclib's own class warnings.
• Expect a reimbursement conversation, not a settled one: confirm the companion diagnostic's coverage before ordering, and do not assume the combination's price or prior-authorization terms mirror either drug's individual history.

Frequently asked questions

What did FDA approve, and for whom?

On 18 September 2026, FDA gave full approval to imlunestrant (Inluriyo) plus abemaciclib (Verzenio), both from Eli Lilly, for adults with ER-positive, HER2-negative, ESR1-mutated, locally advanced or metastatic breast cancer whose disease progressed on at least one prior line of endocrine therapy. It is not approved for patients without a confirmed ESR1 mutation.

When should the ESR1 test be ordered?

Per ASCO's guideline update on ctDNA testing in ER-positive, HER2-negative metastatic breast cancer, blood-based (liquid biopsy) ESR1 testing is recommended at metastatic recurrence or at progression on endocrine therapy — not routinely at initial diagnosis — and repeat testing at each progression is reasonable, since ESR1 mutations typically emerge under the selective pressure of prior endocrine treatment rather than being present from the start.

How does this differ from prescribing elacestrant (Orserdu), the other approved oral SERD for this population?

Both target ESR1-mutated, ER-positive, HER2-negative breast cancer after endocrine therapy, and both now carry Guardant360 CDx as an approved companion diagnostic. The clearest practical difference is monitoring: elacestrant's label calls for a baseline lipid panel and periodic monitoring for hypercholesterolemia and hypertriglyceridemia; imlunestrant's does not carry that requirement. Imlunestrant is also approved and studied specifically as a partner to abemaciclib, not only as monotherapy.

Is reimbursement for the combination established?

Not fully. Guardant360 CDx already has broad payer coverage as a companion diagnostic, including a Medicare (MolDX) local coverage determination for advanced solid tumors, because it was cleared for imlunestrant monotherapy in 2025. Imlunestrant's own list price as monotherapy is disclosed at roughly $22,500 for a 28-day supply. What is not yet public is a combined price or a payer coverage policy specific to the new doublet indication, and prior-authorization terms for prescribing both drugs together under this label have not been separately confirmed.